{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:41:53Z","timestamp":1768351313860,"version":"3.49.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00008","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T04:36:06Z","timestamp":1548736566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Severe Refractory Paraneoplastic Mucous Membrane Pemphigoid Successfully Treated With Rituximab"],"prefix":"10.3389","volume":"6","author":[{"given":"Marcel","family":"Wittenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cden.2013.07.003","article-title":"Mucous membrane pemphigoid","volume":"57","author":"Xu","year":"2013","journal-title":"Dent Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdermsci.2007.02.012","article-title":"A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer","volume":"47","author":"Sadler","year":"2007","journal-title":"J Dermatol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220887","article-title":"Paraneoplastic mucous membrane pemphigoid with ocular and laryngeal involvement","author":"Lambiel","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","article-title":"Anti-epiligrin cicatricial pemphigoid and relative risk for cancer","volume":"357","author":"Egan","year":"2001","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1346-8138.2012.01645.x","article-title":"Anti-laminin-332 mucous membrane pemphigoid with autoantibodies to alpha3, beta3 and gamma2 subunits of laminin-332 as well as to BP230 and periplakin associated with adenocarcinoma from an unknown primary site","volume":"40","author":"Fukuchi","year":"2013","journal-title":"J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/eye.2012.119","article-title":"Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom","volume":"26","author":"Radford","year":"2012","journal-title":"Eye"},{"key":"B11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2013.01.046","article-title":"Treatment of mucous membrane pemphigoid with rituximab","volume":"69","author":"Heelan","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/14712598.2015.1046833","article-title":"Rituximab preserves vision in ocular mucous membrane pemphigoid","volume":"15","author":"R\u00fcbsam","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","article-title":"Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature","volume":"68","author":"Shetty","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bjd.13307","article-title":"Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients","volume":"172","author":"Tomsitz","year":"2015","journal-title":"Br J Dermatol"},{"key":"B17","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2017.05.016","article-title":"Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid","volume":"77","author":"Shimanovich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ajo.2017.08.009","article-title":"Clinical implications of direct immunofluorescence findings in patients with ocular mucous membrane pemphigoid","volume":"183","author":"Labowsky","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/ddg.13569","article-title":"Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement - adjuvant treatment with immunoadsorption and rituximab","volume":"16","author":"Hugel","year":"2018","journal-title":"J Dtsch Dermatol Ges."},{"key":"B21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00105-011-2189-7","article-title":"[Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab]","volume":"62","author":"Recke","year":"2011","journal-title":"Hautarzt"},{"key":"B23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jca.2920050408","article-title":"Therapeutic plasmapheresis and protein A immunoadsorption in malignancy: a brief review","volume":"5","author":"Nand","year":"1990","journal-title":"J Clin Apher"},{"key":"B24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges."},{"key":"B25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2013.1434","article-title":"Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid","volume":"149","author":"Bernard","year":"2013","journal-title":"JAMA Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T04:36:06Z","timestamp":1548736566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":25,"alternative-id":["10.3389\/fmed.2019.00008"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00008","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"article-number":"8"}}